Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 20,000 Shares of Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $15.92, for a total value of $318,400.00. Following the transaction, the insider now directly owns 604,205 shares in the company, valued at approximately $9,618,943.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jaume Pons also recently made the following trade(s):

• On Tuesday, April 16th, Jaume Pons sold 50,000 shares of ALX Oncology stock. The shares were sold at an average price of $14.20, for a total transaction of $710,000.00.
• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00.

ALX Oncology Trading Up 2.0 %

Shares of NASDAQ ALXO opened at $16.95 on Friday. The stock has a fifty day simple moving average of $13.74 and a 200-day simple moving average of $12.75. ALX Oncology Holdings Inc. has a twelve month low of $3.94 and a twelve month high of $17.83. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $847.50 million, a PE ratio of -4.52 and a beta of 1.30.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). On average, equities analysts forecast that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALXO. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of ALX Oncology in the fourth quarter valued at $28,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of ALX Oncology by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock valued at $107,000 after buying an additional 3,825 shares during the period. Barclays PLC grew its position in shares of ALX Oncology by 57.1% during the third quarter. Barclays PLC now owns 26,964 shares of the company’s stock worth $129,000 after buying an additional 9,796 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of ALX Oncology during the third quarter worth approximately $48,000. Finally, Forefront Analytics LLC acquired a new stake in ALX Oncology in the third quarter valued at approximately $66,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALXO has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a research report on Wednesday, April 10th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, ALX Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $18.83.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.